Profil bibliographique

Antonella Isacchi

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

236Publications signalées

6550Citations signalées

1Affiliations récentes

Les institutions déclarées

Nerviano Medical Sciences

Les domaines associés

Microtubule and mitosis dynamicsHER2/EGFR in Cancer ResearchCancer-related Molecular PathwaysLung Cancer Treatments and MutationsHeat shock proteins research

Les publications récentes

Accès ouvert 2023 other OpenAlex

Table S5 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies

Barbara Valsasina, Paolo Orsini, Michele Caruso, Clara Albanese et autres

NMS-P945 stability in plasma

0 citations

Accès ouvert 2023 other OpenAlex

Table S6 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies

Barbara Valsasina, Paolo Orsini, Michele Caruso, Clara Albanese et autres

NMS-P945 trastuzumab ADC PK data

0 citations

Accès ouvert 2023 other OpenAlex

Data from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies

Barbara Valsasina, Paolo Orsini, Michele Caruso, Clara Albanese et autres

Abstract New antibodies–drug conjugate (ADC) payloads overcoming chemoresistance and killing also poorly proliferating tumors at well-tolerated doses are much desired. Duocarmycins are a well-known class of highly potent cytotoxic agents, with DNA minor groove-binding and alkylation properties, active also in chemoresistant tumors. …

0 citations

Accès ouvert 2023 other OpenAlex

Figure S2 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies

Barbara Valsasina, Paolo Orsini, Michele Caruso, Clara Albanese et autres

Half-life determination of NMS-P528 +self immolative spacer at different pH and timepoints

0 citations

Accès ouvert 2023 other OpenAlex

Figure S3 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies

Barbara Valsasina, Paolo Orsini, Michele Caruso, Clara Albanese et autres

Biochemical characterization of trastuzumab conjugated to MMAE and Deruxtecan

0 citations

Accès ouvert 2023 other OpenAlex

Table S2 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies

Barbara Valsasina, Paolo Orsini, Michele Caruso, Clara Albanese et autres

Payload antiproliferative activity

0 citations

Accès ouvert 2023 other OpenAlex

Table S3 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies

Barbara Valsasina, Paolo Orsini, Michele Caruso, Clara Albanese et autres

Antiproliferative activity of NMS-P528, MMAE, DXd and doxorubicin in parental and MDR expressing cell lines

0 citations

Accès ouvert 2023 other OpenAlex

Table S2 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies

Barbara Valsasina, Paolo Orsini, Michele Caruso, Clara Albanese et autres

Payload antiproliferative activity

0 citations

Accès ouvert 2023 other OpenAlex

Table S1 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies

Barbara Valsasina, Paolo Orsini, Michele Caruso, Clara Albanese et autres

Cell lines used in the study with providers, date of master banking and growth media compositions

0 citations

Accès ouvert 2023 other OpenAlex

Table S4 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies

Barbara Valsasina, Paolo Orsini, Michele Caruso, Clara Albanese et autres

Stability of NMS-P528 in mouse, rat, monkey and human plasma

0 citations

Accès ouvert 2023 other OpenAlex

Data from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies

Barbara Valsasina, Paolo Orsini, Michele Caruso, Clara Albanese et autres

Abstract New antibodies–drug conjugate (ADC) payloads overcoming chemoresistance and killing also poorly proliferating tumors at well-tolerated doses are much desired. Duocarmycins are a well-known class of highly potent cytotoxic agents, with DNA minor groove-binding and alkylation properties, active also in chemoresistant tumors. …

0 citations

Accès ouvert 2023 other OpenAlex

Table S5 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies

Barbara Valsasina, Paolo Orsini, Michele Caruso, Clara Albanese et autres

NMS-P945 stability in plasma

0 citations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.